Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer Intervention: Drug: Individualized neoantigen peptides vaccine Sponsors: Sun Yat-sen University; Tianjin Hengjia Biotechnology Development co., LTD Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Vaccines | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study | Vaccines